1. Home
  2. ITRG vs ASMB Comparison

ITRG vs ASMB Comparison

Compare ITRG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

N/A

Current Price

$2.24

Market Cap

486.9M

ML Signal

N/A

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

N/A

Current Price

$20.38

Market Cap

512.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ITRG
ASMB
Founded
1997
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.9M
512.1M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
ITRG
ASMB
Price
$2.24
$20.38
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
$5.75
★ $51.20
AVG Volume (30 Days)
★ 1.5M
190.9K
Earning Date
11-11-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.78
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.41
N/A
Revenue Next Year
$26.85
N/A
P/E Ratio
$45.07
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$19.25
52 Week High
$4.87
$39.71

Technical Indicators

Market Signals
Indicator
ITRG
ASMB
Relative Strength Index (RSI) 42.67 44.99
Support Level $2.00 $19.30
Resistance Level $2.30 $21.65
Average True Range (ATR) 0.11 1.03
MACD 0.00 0.29
Stochastic Oscillator 46.27 60.07

Price Performance

Historical Comparison
ITRG
ASMB

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: